LENZ Therapeutics (NASDAQ:LENZ) Rating Reiterated by Leerink Partnrs

LENZ Therapeutics (NASDAQ:LENZ)‘s stock had its “outperform” rating restated by Leerink Partnrs in a report issued on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

Other equities research analysts have also recently issued reports about the company. Piper Sandler started coverage on LENZ Therapeutics in a research report on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price objective on the stock. Citigroup started coverage on LENZ Therapeutics in a report on Wednesday, April 10th. They issued a “buy” rating and a $34.00 target price on the stock. SVB Leerink started coverage on LENZ Therapeutics in a report on Monday. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, William Blair started coverage on LENZ Therapeutics in a report on Monday. They issued an “outperform” rating on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $31.33.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock traded down $2.22 during trading on Monday, hitting $17.70. 84,141 shares of the company’s stock traded hands, compared to its average volume of 58,430. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82. The stock has a market capitalization of $147.26 million, a PE ratio of -1.13 and a beta of 0.20.

Insider Transactions at LENZ Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 998,009 shares of the firm’s stock in a transaction dated Thursday, March 21st. The shares were purchased at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now directly owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.